Search

Your search keyword '"Di Mauro, Marina"' showing total 49 results
Start Over Author "Di Mauro, Marina"
49 results on '"Di Mauro, Marina"'

2. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.

Author

Maggi, Martina, Del Giudice, Francesco, Falagario, Ugo G, Cocci, Andrea, Russo, Giorgio Ivan, Di Mauro, Marina, Sepe, Giuseppe Salvatore, Galasso, Fabio, Leonardi, Rosario, Iacona, Gabriele, Carroll, Peter R, Cooperberg, Matthew R, Porreca, Angelo, Ferro, Matteo, Lucarelli, Giuseppe, Terracciano, Daniela, Cormio, Luigi, Carrieri, Giuseppe, De Berardinis, Ettore, Sciarra, Alessandro, and Busetto, Gian Maria

Subjects
PSA, early detection, mpMRI, prostate biopsy, prostate neoplasm, urinary biomarker, Oncology and Carcinogenesis
Abstract

Prostate-specific antigen (PSA) testing as the sole indication for prostate biopsy lacks specificity, resulting in overdiagnosis of indolent prostate cancer (PCa) and missing clinically significant PCa (csPCa). SelectMDx is a biomarker-based risk score to assess urinary HOXC6 and DLX1 mRNA expression combined with traditional clinical risk factors. The aim of this prospective multi-institutional study was to evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance (mpMRI) when predicting PCa in prostate biopsies. Overall, 310 consecutive subjects were included. All patients underwent mpMRI and SelectMDx prior to prostate biopsy. SelectMDx and mpMRI showed sensitivity and specificity of 86.5% vs. 51.9%, and 73.8% vs. 88.3%, respectively, in predicting PCa at biopsy, and 87.1% vs. 61.3%, and 63.7% vs. 83.9%, respectively, in predicting csPCa at biopsy. SelectMDx was revealed to be a good predictor of PCa, while with regards to csPCa detection, it was demonstrated to be less effective, showing results similar to mpMRI. With analysis of strategies assessed to define the best diagnostic strategy to avoid unnecessary biopsy, SelectMDx appeared to be a reliable pathway after an initial negative mpMRI. Thus, biopsy could be proposed for all cases of mpMRI PI-RADS 4-5 score, and to those with Prostate Imaging-Reporting and Data System (PI-RADS) 1-3 score followed by a positive SelectMDx.

Published
2021

10. Patients' perceptions of quality of care delivery by urology residents: A nationwide study

Author

Mantica, Guglielmo, Chierigo, Francesco, Gallo, Fabio, Cocci, Andrea, Esperto, Francesco, Patruno, Giulio, Diminutto, Alberto, Cerasuolo, Mattia, Campi, Riccardo, Barale, Maurizio, Ragonese, Mauro, Bettin, Laura, Zanetti, Stefano, Bianchi, Lorenzo, Principi, Emanuele, Puliatti, Stefano, Cancrini, Fabiana, Parnanzini, Daniele, Bianchi, Grazia, Grande, Pietro, Primiceri, Giulia, Cavacece, Fernando, Schiralli, Pasquale, Amparore, Daniele, Farullo, Giuseppe, Di Mauro, Marina, Durante, Jacopo, Baldesi, Ramona, Carobbio, Francesca, Russo, Giorgio I, Luperto, Elia, La Rocca, Roberto, and Cacciamani, Giovanni E

Subjects
urological education, urology residents, Urologists, Surveys and Questionnaires, Urology, urology, patient's perspective, survey, Humans, Internship and Residency, #Urology, Clinical Competence
Abstract

To present the results of a nationwide survey among urological patients to evaluate their perception of the quality of care provided by residents.An anonymous survey was distributed to patients who were referred to 22 Italian academic institutions. The survey aimed to investigate the professional figure of the urology resident as perceived by the patient.A total of 2587 patients were enrolled in this study. In all, 51.6% of patients were able to correctly identify a urology resident; however, almost 40% of respondents discriminated residents from fully trained urologists based exclusively on their young age. Overall, 98.2% patients rated the service provided by the resident as at least sufficient. Urology trainees were considered by more than 50% of the patients interviewed to have good communication skills, expertise and willingness. Overall, patients showed an excellent willingness to be managed by urology residents. The percentage of patients not available for this purpose showed an increasing trend that directly correlated with the difficulty of the procedure. Approximately 5-10% of patients were not willing to be managed by residents for simple procedures such as clinical visits, cystoscopy or sonography, and up to a third of patients were not prepared to undergo any surgical procedure performed by residents during steps in major surgery, even if the residents were adequately tutored.Our data showed that patients have a good willingness to be managed by residents during their training, especially for medium- to low-difficulty procedures. Furthermore, the majority of patients interviewed rated the residents' care delivery as sufficient. Urology trainees were considered to have good communication skills, expertise and willingness.

Published
2022
Full Text
View/download PDF

12. A survey on preferences, attitudes, and perspectives of Italian urology trainees: implications of the novel national residency matching program.

Author

NAPOLITANO, Luigi, MAGGI, Martina, SAMPOGNA, Gianluca, BIANCO, Marta, CAMPETELLA, Marco, CARILLI, Marco, CHIARISSI, Marco LUCCI, CIVITELLA, Angelo, DE VITA, Francesco, DI MAIDA, Fabrizio, DI MAURO, Marina, ERCOLINO, Amelio, FASULO, Vittorio, FELICI, Graziano, GHEZA, Alberto, GUZZARDO, Calogero, LOIZZO, Davide, MAZZONE, Elio, PARODI, Stefano, and PIRAMIDE, Federico

Published
2023
Full Text
View/download PDF

13. PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer

Author

Russo, Giorgio Ivan, primary, Musso, Nicolò, additional, Lo Giudice, Arturo, additional, Asmundo, Maria Giovanna, additional, Di Mauro, Marina, additional, Bonacci, Paolo G., additional, Massimino, Mariacristina, additional, Bivona, Dalida, additional, Stefani, Stefania, additional, Pricoco, Elisabetta, additional, Ferro, Matteo, additional, Camarda, Massimo, additional, Cimino, Sebastiano, additional, Morgia, Giuseppe, additional, Caltabiano, Rosario, additional, and Broggi, Giuseppe, additional

Published
2022
Full Text
View/download PDF

15. MP53-10 THE ROLE OF SELECTMDX IN MEN UNDERGOING PRIMARY PROSTATE BIOPSY: A PROSPECTIVE MULTI-INSTITUTIONAL STUDY

Author

Maggi, Martina, primary, Del Giudice, Francesco, additional, Falagario, Ugo G., additional, Cocci, Andrea, additional, Russo, Giorgio I., additional, Di Mauro, Marina, additional, Sepe, Giuseppe Salvatore, additional, Galasso, Fabio, additional, Leonardi, Rosario, additional, Iacona, Gabriele, additional, Carroll, Peter R., additional, Cooperberg, Matthew R., additional, Porreca, Angelo, additional, Ferro, Matteo, additional, Lucarelli, Giuseppe, additional, Terracciano, Daniela, additional, Cormio, Luigi, additional, Carrieri, Giuseppe, additional, De Berardinis, Ettore, additional, Sciarra, Alessandro, additional, and Busetto, Gian Maria, additional

Published
2022
Full Text
View/download PDF

17. Sexual Behaviour and Fantasies in a Group of Young Italian Cohort

Author

Di Mauro, Marina, primary, Russo, Giorgio Ivan, additional, Polloni, Gaia, additional, Tonioni, Camilla, additional, Giunti, Daniel, additional, Cito, Gianmartin, additional, Giammusso, Bruno, additional, Morelli, Girolamo, additional, Masieri, Lorenzo, additional, and Cocci, Andrea, additional

Published
2021
Full Text
View/download PDF

19. SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

Author

Broggi, Giuseppe, primary, Lo Giudice, Arturo, additional, Di Mauro, Marina, additional, Asmundo, Maria Giovanna, additional, Pricoco, Elisabetta, additional, Piombino, Eliana, additional, Caltabiano, Rosario, additional, Morgia, Giuseppe, additional, and Russo, Giorgio Ivan, additional

Published
2021
Full Text
View/download PDF

20. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement:A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials

Author

Russo, Giorgio Ivan, Scandura, Carmen, Di Mauro, Marina, Cacciamani, Giovanni, Albersen, Maarten, Hatzichristodoulou, Georgios, Fode, Mikkel, Capogrosso, Paolo, Cimino, Sebastiano, Marcelissen, Tom, Cornu, Jean Nicolas, Gacci, Mauro, Minervini, Andrea, Cocci, Andrea, Russo, Giorgio Ivan, Scandura, Carmen, Di Mauro, Marina, Cacciamani, Giovanni, Albersen, Maarten, Hatzichristodoulou, Georgios, Fode, Mikkel, Capogrosso, Paolo, Cimino, Sebastiano, Marcelissen, Tom, Cornu, Jean Nicolas, Gacci, Mauro, Minervini, Andrea, and Cocci, Andrea

Abstract

Context: International guidelines do not make any specific recommendations on Serenoa repens (SeR) for the treatment of male lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE), due to product heterogeneity and methodological limitations of the published trials and meta-analyses.Objective: We aimed to compare the clinical efficacy of hexanic extract of SeR (HESr) versus non-HESr (nHESr) versus placebo versus alpha-blockers (ABs) in patients affected by LUTS secondary to BPE through a network meta-analysis method.Evidence acquisition: The search was conducted until December 31, 2018 using Medline, Scopus, and Web of Science databases without restriction. We included randomized controlled trials (RCTs) with at least one comparison between SeR, ABs, or placebo for the treatment of LUTS/BPE. Outcomes of the study were the mean change in the International Prostate Symptom Score (IPSS) and peak flow (PF). This systematic review has been registered on PROSPERO (CRD42018084360).Evidence synthesis: In total, 2115 articles were identified. After the global assessment, 22 RCTs matched with the inclusion criteria, including 8564 patients. For IPSS, the mean efficacies against placebo were +0.48 and -1.69 for HESr and nHESr, respectively, at 3 mo; 0.59 for nHESr at 6 mo; and -1.31 and -3.30 for nHESrand HESr, respectively, at 12 mo. For PF, the mean efficacies against placebo were +0.53 and +2.82 for HESr and nHESr, respectively, at 3 mo; +1.85 for nHESrat 6 mo; and +4.05 and +5.52 for HESrand nHESr, respectively, at 12 mo. Based on the surface under the cumulative ranking curve rankograms, terazosin showed the highest score (99.6%), whilealfuzosin, tamsulosin, silodosin, HESr, and nHESr showedscores of 53.7%, 42.3%, 68.5%, 36.7%, and 47.3%, respectively.Conclusions: In this network meta-analysis, we demonstrated that SeR did not show clinically meaningful improvement in LUTS and PF.Patient summary: In the pre

Published
2021

21. The impact of asexual trait and porn addiction in a young men healthy cohort

Author

Russo, Giorgio Ivan, Campisi, Daniele, Di Mauro, Marina, Falcone, Marco, Cocci, Andrea, Cito, Gianmartin, Verze, Paolo, Capogrosso, Paolo, Fode, Mikkel, Cacciamani, Giovanni, Morgia, Giuseppe, Russo, Giorgio Ivan, Campisi, Daniele, Di Mauro, Marina, Falcone, Marco, Cocci, Andrea, Cito, Gianmartin, Verze, Paolo, Capogrosso, Paolo, Fode, Mikkel, Cacciamani, Giovanni, and Morgia, Giuseppe

Abstract

In the present study, we aimed to evaluate the association between asexual trait, erectile dysfunction (ED) and porn addiction in a community sample of young men. Between August 2019 and October 2019, a total of 559 young male adults were subjected to an online survey sponsored by social networks with the aim of assessing their sexual habits. The following questionnaires were administered: The International Index of Erectile Function (IIEF-5), Masturbation Erection index (MEI), Pornography Craving Questionnaire (PCQ) and Asexuality Identification Scale (AIS). The overall rate of ED according to IIEF-5 was 26.0% (165/478), the rate of ED according to MEI was 16.9% (81/478) and the rate ED in patients with AIS ≥23 indicating asexual trait was 10.0% (48/478). We found that IIEF-5 was positively associated with MEI (b = 0.32; p <.01) and negatively with AIS (b = −0.36; p <.01) and MEI was negatively associated with AIS (b = −0.36; p <.01). We found that MEI (odds ratio [OR]: 0.86; p <.01) and IIEF-5 (OR: 0.89; p <.01) were inversely associated with asexual trait. The presence of asexual trait can hide a greater risk of finding ED both in intercourse or masturbation. These results should be taken into consideration during the general assessment of the patient with sexual problems.

Published
2021

22. The role of renal biopsy to improve small renal mass diagnosis and management: are there predictive factors for a higher detection rate?. The first Italian study of 100 cases

Author

BADA, Maida, primary, RAPISARDA, Sebastiano, additional, CICERO, Calogero, additional, DI MAURO, Marina, additional, SEBBEN, Marco, additional, DE CONCILIO, Bernardino, additional, ZECCOLINI, Guglielmo, additional, MAZZON, Giorgio, additional, and CELIA, Antonio, additional

Published
2021
Full Text
View/download PDF

23. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials

Author

Russo, Giorgio Ivan, primary, Scandura, Carmen, additional, Di Mauro, Marina, additional, Cacciamani, Giovanni, additional, Albersen, Maarten, additional, Hatzichristodoulou, Georgios, additional, Fode, Mikkel, additional, Capogrosso, Paolo, additional, Cimino, Sebastiano, additional, Marcelissen, Tom, additional, Cornu, Jean Nicolas, additional, Gacci, Mauro, additional, Minervini, Andrea, additional, and Cocci, Andrea, additional

Published
2021
Full Text
View/download PDF

24. Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance

Author

Ferro, Matteo, primary, Musi, Gennaro, additional, Matei, Deliu Victor, additional, Mistretta, Alessandro Francesco, additional, Luzzago, Stefano, additional, Cozzi, Gabriele, additional, Bianchi, Roberto, additional, Di Trapani, Ettore, additional, Cioffi, Antonio, additional, Lucarelli, Giuseppe, additional, Busetto, Gian Maria, additional, Del Giudice, Francesco, additional, Russo, Giorgio Ivan, additional, Di Mauro, Marina, additional, Porreca, Angelo, additional, Renne, Giuseppe, additional, Catellani, Michele, additional, Bottero, Danilo, additional, Brescia, Antonio, additional, Cordima, Giovanni, additional, and de Cobelli, Ottavio, additional

Published
2021
Full Text
View/download PDF

25. Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer

Author

Ferro, Matteo, primary, Di Mauro, Marina, additional, Cimino, Sebastiano, additional, Morgia, Giuseppe, additional, Lucarelli, Giuseppe, additional, Abu Farhan, Abdal Rahman, additional, Vartolomei, Mihai Dorin, additional, Porreca, Angelo, additional, Cantiello, Francesco, additional, Damiano, Rocco, additional, Busetto, Gian Maria, additional, Del Giudice, Francesco, additional, Hurle, Rodolfo, additional, Perdonà, Sisto, additional, Borghesi, Marco, additional, Bove, Pierluigi, additional, Autorino, Riccardo, additional, Crisan, Nicolae, additional, Marchioni, Michele, additional, Schips, Luigi, additional, Soria, Francesco, additional, Mari, Andrea, additional, Minervini, Andrea, additional, Veccia, Alessandro, additional, Battaglia, Michele, additional, Terracciano, Daniela, additional, Musi, Gennaro, additional, Cordima, Giovanni, additional, Muto, Matteo, additional, Mirone, Vincenzo, additional, de Cobelli, Ottavio, additional, and Russo, Giorgio Ivan, additional

Published
2021
Full Text
View/download PDF

26. The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review

Author

Russo, Giorgio Ivan, primary, Larganà, Gaetano, additional, Sebastianelli, Arcangelo, additional, Cocci, Andrea, additional, Di Mauro, Marina, additional, Rapallo, Ilenia, additional, Morgia, Giuseppe, additional, Morgia, Matteo Mario, additional, La Vignera, Sandro, additional, Condorelli, Rosita, additional, Calogero, Aldo E., additional, Olivotto, Iacopo, additional, Morselli, Simone, additional, Serni, Sergio, additional, and Gacci, Mauro, additional

Published
2021
Full Text
View/download PDF

27. Mechanical and Ablative Minimally Invasive Techniques for Male LUTS due to Benign Prostatic Obstruction: A Systematic Review according to BPH-6 Evaluation

Author

Cantiello, Francesco, primary, Fimognari, Deborah, additional, Di Mauro, Marina, additional, Crocerossa, Fabio, additional, Carbonara, Umberto, additional, Ferro, Matteo, additional, De Cobelli, Ottavio, additional, Lucarelli, Giuseppe, additional, De Nunzio, Cosimo, additional, Morgia, Giuseppe, additional, Damiano, Rocco, additional, Autorino, Riccardo, additional, Porpiglia, Francesco, additional, and Russo, Giorgio Ivan, additional

Published
2021
Full Text
View/download PDF

28. Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study

Author

Cocci, Andrea, primary, Di Maida, Fabrizio, additional, Cito, Gianmartin, additional, Verrienti, Pierangelo, additional, Laruccia, Nicola, additional, Campi, Riccardo, additional, Mari, Andrea, additional, Di Mauro, Marina, additional, Falcone, Marco, additional, Cacciamani, Giovanni E., additional, Garaffa, Giulio, additional, Minervini, Andrea, additional, and Russo, Giorgio Ivan, additional

Published
2021
Full Text
View/download PDF

29. Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience

Author

Scicali, Roberto, primary, Russo, Giorgio Ivan, additional, Di Mauro, Marina, additional, Manuele, Flavia, additional, Di Marco, Grazia, additional, Di Pino, Antonino, additional, Ferrara, Viviana, additional, Rabuazzo, Agata Maria, additional, Piro, Salvatore, additional, Morgia, Giuseppe, additional, and Purrello, Francesco, additional

Published
2020
Full Text
View/download PDF

32. Can cytomegalovirus infection affect male reproductive function? Results of a retrospective single‐centre analysis

Author

Cito, Gianmartin, primary, Coccia, Maria Elisabetta, additional, Picone, Rita, additional, Fucci, Rossella, additional, Micelli, Elisabetta, additional, Cocci, Andrea, additional, Di Mauro, Marina, additional, Rizzello, Francesca, additional, Giachini, Claudia, additional, Minervini, Andrea, additional, Carini, Marco, additional, and Natali, Alessandro, additional

Published
2020
Full Text
View/download PDF

33. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials

Author

Russo, Giorgio Ivan, Scandura, Carmen, Di Mauro, Marina, Cacciamani, Giovanni, Albersen, Maarten, Hatzichristodoulou, Georgios, Fode, Mikkel, Capogrosso, Paolo, Cimino, Sebastiano, Marcelissen, Tom, Cornu, Jean Nicolas, Gacci, Mauro, Minervini, Andrea, Cocci, Andrea, European, EAU - YAU, Urology Section, University of Catania, Catania, Italy, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA, Department of Urology, University Hospitals Leuven, Leuven, Belgium., Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany., Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Urology Section, University of Catania, Catania, Italy., Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), and European Association of Urology Young Academic Urologists (EAU-YAU) Men’s Health and Functional Urology Working Groups.

Subjects
Male, medicine.medical_specialty, Medical therapy, Urology, Network Meta-Analysis, 030232 urology & nephrology, Prostatic Hyperplasia, Placebo, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, SILODOSIN, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Lower Urinary Tract Symptoms, Lower urinary tract symptoms, Saw palmetto, Tamsulosin, law, Serenoa, medicine, Humans, 10. No inequality, HYPERPLASIA, Alfuzosin, ComputingMilieux_MISCELLANEOUS, Randomized Controlled Trials as Topic, Benign prostatic hyperplasia, business.industry, Plant Extracts, Prostate, EXTRACT, MEN, Silodosin, medicine.disease, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, SAFETY, International Prostate Symptom Score, business, medicine.drug, Phytotherapy
Abstract

Context: International guidelines do not make any specific recommendations on Serenoa repens (SeR) for the treatment of male lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE), due to product heterogeneity and methodological limitations of the published trials and meta-analyses.Objective: We aimed to compare the clinical efficacy of hexanic extract of SeR (HESr) versus non-HESr (nHESr) versus placebo versus alpha-blockers (ABs) in patients affected by LUTS secondary to BPE through a network meta-analysis method.Evidence acquisition: The search was conducted until December 31, 2018 using Medline, Scopus, and Web of Science databases without restriction. We included randomized controlled trials (RCTs) with at least one comparison between SeR, ABs, or placebo for the treatment of LUTS/BPE. Outcomes of the study were the mean change in the International Prostate Symptom Score (IPSS) and peak flow (PF). This systematic review has been registered on PROSPERO (CRD42018084360).Evidence synthesis: In total, 2115 articles were identified. After the global assessment, 22 RCTs matched with the inclusion criteria, including 8564 patients. For IPSS, the mean efficacies against placebo were +0.48 and -1.69 for HESr and nHESr, respectively, at 3 mo; 0.59 for nHESr at 6 mo; and -1.31 and -3.30 for nHESrand HESr, respectively, at 12 mo. For PF, the mean efficacies against placebo were +0.53 and +2.82 for HESr and nHESr, respectively, at 3 mo; +1.85 for nHESrat 6 mo; and +4.05 and +5.52 for HESrand nHESr, respectively, at 12 mo. Based on the surface under the cumulative ranking curve rankograms, terazosin showed the highest score (99.6%), whilealfuzosin, tamsulosin, silodosin, HESr, and nHESr showedscores of 53.7%, 42.3%, 68.5%, 36.7%, and 47.3%, respectively.Conclusions: In this network meta-analysis, we demonstrated that SeR did not show clinically meaningful improvement in LUTS and PF.Patient summary: In the present study, we found no clinically meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement. The analysis showed that the benefit over placebo was minimal and may not justify its clinical use before higher level of evidence will be available. (C) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Published
2020
Full Text
View/download PDF

34. How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?

Author

Cocci, Andrea, primary, Di Maida, Fabrizio, additional, Russo, Giorgio Ivan, additional, di Mauro, Marina, additional, Cito, Gianmartin, additional, Falcone, Marco, additional, Minervini, Andrea, additional, Cacciamani, Giovanni, additional, Campi, Riccardo, additional, Mari, Andrea, additional, Sessa, Francesco, additional, and Mondaini, Nicola, additional

Published
2020
Full Text
View/download PDF

35. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study)

Author

Morgia, Giuseppe, Vespasiani, Giuseppe, Pareo, Rosaria M., Voce, Salvatore, Madonia, Massimo, Carini, Marco, Ingrassia, Antonio, Terrone, Carlo, Gentile, Marcello, Carrino, Maurizio, Giannantoni, Antonella, Blefari, Franco, Arnone, Salvatore, Santelli, Giorgio, Russo, Giorgio I., Reale, Giulio, Di Mauro, Marina, Fedelini, Paolo, Pucci, Luigi, Veneziano, Pasquale, Santaniello, Francesco, Ginepri, Andrea, Bitelli, Marco, Valerio Beatrici, M., Polledro, Patrizio, La Rosa, Pasquale, Chiancone, Francesco, Giannella, Riccardo, Del Fabbro, Dario, Farullo, Giuseppe, Cocci, Andrea, Lanciotti, Michele, Solinas, Tatiana, Di Dio, Agata, Dal Pozzo, Claudio, Palmieri, Fabiano, Zaganelli, Stefano, and Lacetera, Vito

Subjects
Male, benign prostatic enlargement, LUTS, prostate, Serenoa repens, tadalafil, medicine.medical_specialty, Urology, 030232 urology & nephrology, Prostatic Hyperplasia, Group B, law.invention, Tadalafil, 03 medical and health sciences, Selenium, 0302 clinical medicine, Lycopene, Randomized controlled trial, Lower Urinary Tract Symptoms, law, Lower urinary tract symptoms, Serenoa, medicine, Clinical endpoint, 80 and over, Humans, Adverse effect, Benign prostatic enlargement, Prostate, Aged, Aged, 80 and over, business.industry, Plant Extracts, Middle Aged, Phosphodiesterase 5 Inhibitors, medicine.disease, Drug Combinations, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Tablets, Urological Agents, International Prostate Symptom Score, business, medicine.drug
Abstract

OBJECTIVE To compare in a randomised, open-label, non-inferiority clinical study, the efficacy and tolerability of Serenoa repens (SeR) + selenium (Se) + lycopene (Ly) (SeR-Se-Ly) therapy vs tadalafil 5 mg in men with lower urinary tract symptoms (LUTS). PATIENTS AND METHODS From May 2015 to January 2017, 427 patients were enrolled in 21 different centres (International Standard Randomised Controlled Trial Number Register [ISRCTN] 73316039). Inclusion criteria included: age between 50 and 80 years, International Prostate Symptom Score (IPSS) ≥12, maximum urinary flow rate (Qmax ) ≤ 15 mL/s, and post-void residual (PVR)

Published
2018

37. Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study

Author

di Mauro, Marina, primary, Russo, Giorgio Ivan, additional, Della Camera, Pier Andrea, additional, di Maida, Fabrizio, additional, Cito, Gianmartin, additional, Mondaini, Nicola, additional, Capece, Marco, additional, Falcone, Marco, additional, Sessa, Francesco, additional, Mari, Andrea, additional, Campi, Riccardo, additional, Sabini, Carlotta, additional, Serni, Sergio, additional, Gacci, Mauro, additional, Minervini, Andrea, additional, Carini, Marco, additional, Cimino, Sebastiano, additional, Morelli, Girolamo, additional, and Cocci, Andrea, additional

Published
2019
Full Text
View/download PDF

40. MP09-04 COMPARISON BETWEEN TADALAFIL 5 MG VS. SERENOA REPENS/SELENIUM/LYCOPENE FOR THE TREATMENT OF BENIGN PROSTATIC LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA. A PHASE IV, RANDOMIZED, MULTICENTER, NON-INFERIORITY CLINICAL STUDY. SPRITE STUDY.

Author

Morgia, Giuseppe, primary, Reale, Giulio, additional, Vespasiani, Giuseppe, additional, Di Mauro, Marina, additional, Pareo, Rosaria M., additional, Voce, Salvatore, additional, Madonia, Massimo, additional, Fedelini, Paolo, additional, Veneziano, Pasquale, additional, Carini, Marco, additional, Salvia, Giuseppe, additional, Santaniello, Francesco, additional, Ginepri, Andrea, additional, Bitelli, Marco, additional, Terrone, Carlo, additional, Gentile, Marcello, additional, Giannantoni, Antonella, additional, Blefari, Franco, additional, Beatrici, Valerio, additional, Polledro, Patrizio, additional, La Rosa, Pasquale, additional, Arnone, Salvatore, additional, Santelli, Giorgio, additional, and Russo, Giorgio Ivan, additional

Published
2017
Full Text
View/download PDF

42. Consulting “Dr Google” for sexual dysfunction: a contemporary worldwide trend analysis

Author

Russo, Giorgio Ivan, di Mauro, Marina, Cocci, Andrea, Cacciamani, Giovanni, Cimino, Sebastiano, Serefoglu, Ege Can, Albersen, Maarten, Capogrosso, Paolo, Fode, Mikkel, and Verze, Paolo

Abstract

Google Trends (GT) is a free, easily accessible search tool which can be used to analyze worldwide “big data” on the relative popularity of search terms over a specific period of time. To determine worldwide public interest in Peyronie’ disease (PD), erectile dysfunction (ED), premature ejaculation (PE) treatments, their penetrance, variation, and how they compare over time. Worldwide search-engine trends analysis included electronic Google queries from people who searched PD, ED, and PE treatments options from January 2004 to October 2018, worldwide. Join-point regression (JPR) has been performed. Comparison annual relative search volume (ARSV), average annual percentage change (AAPC) and temporal patterns were analyzed to assess loss or gain of interest. Our results showed that for PD it has been a decreased interest for Drug (AAPC: −3.1%, p< 0.01), ESWT (AAPC: −3.1%, p< 0.01), and vacuum therapy (AAPC: −1.2%, p< 0.01). In the field of ED, we observed trends toward an increased interest in prosthetic surgical treatment (AAPC: +1.7%, p= 0.4), for prostaglandins (AAPC: +0.7%, p= 0.7), for traction (AAPC: +0.6%, p= 0.1) and for ESWT (AAPC: +1.8%, p= 0.4), but without statistical significance. On the contrary, we observed a slight reduction of search for Vacuum device (AAPC: −1 %, p< 0.01). The interest in PE decreased from 2004 to today (AAPC: −1%, p< 0.01), for surgical treatment (AAPC: −3.1%, p< 0.01), drug treatment (AAPC: −3.1%, p< 0.01), and for psychotherapy (AAPC: −6.7%, p< 0.01). On the contrary, the interest in spray drugs has increased significantly (AAPC: +5.1%, p< 0.01). Patients are searching the web for sexual diseases treatment options. Understanding people inquisitiveness together with degree of knowledge could be supportive to guide counseling in the decision-making-process and put effort in certifying patient information, avoiding them to fall in the pernicious trap of ‘fake-news’.

Published
2020
Full Text
View/download PDF

43. Association between dietary phytoestrogens intakes and prostate cancer risk in Sicily.

Author

Russo, Giorgio I., Di Mauro, Marina, Regis, Federica, Reale, Giulio, Campisi, Daniele, Marranzano, Marina, Lo Giudice, Arturo, Solinas, Tatiana, Madonia, Massimo, Cimino, Sebastiano, and Morgia, Giuseppe

Subjects
*PHYTOESTROGENS, *PROSTATE cancer risk factors, *MEDITERRANEAN diet, *CASE-control method, *LOGISTIC regression analysis, *LIGNANS, *DIET, *PROSTATE, *PROSTATE tumors, *SURVEYS, *GENISTEIN, *PREVENTION
Abstract

Objective: In this study we aimed to investigate the association between dietary phytoestrogen consumption and prostate cancer in a sample of southern Italian individuals.Methods: A population-based case-control study on the association between prostate cancer and dietary factors was conducted from January 2015 to December 2016 in a single institution of the municipality of Catania, southern Italy (Registration number: 41/2015). A total of 118 histopathological-verified prostate cancer (PCa) cases and a total of 222 controls were collected. Dietary data was collected by using two food frequency questionnaires.Results: Patients with PCa consumed significantly higher levels of phytoestrogens. Multivariate logistic regression showed that lignans (Q[quartile]4 vs. Q1, OR [odds ratio] = 4.72; p < .05) and specifically, lariciresinol (Q4 vs. Q1, OR = 4.60; p < .05), pinoresinol (Q4 vs. Q1, OR = 5.62; p < .05), matairesinol (Q4 vs. Q1, OR = 3.63; p < .05), secoisolariciresinol (Q4 vs. Q1, OR = 4.10; p < .05) were associated with increased risk of PCa. Furthermore, we found that isoflavones (Q3 vs. Q1, OR = 0.28; p < .05) and specifically, genistein (Q4 vs. Q1, OR = 0.40; p < .05) were associated with reduced risk of PCa.Conclusion: We found of an inverse association between dietary isoflavone intake and PCa, while a positive association was found with lignans intake. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

45. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study

Author

Alessandro Sciarra, Daniela Terracciano, Angelo Porreca, Giuseppe Lucarelli, Rosario Leonardi, Francesco Del Giudice, Gian Maria Busetto, Martina Maggi, Matthew R. Cooperberg, Ugo Falagario, Luigi Cormio, Giuseppe Carrieri, Giuseppe Salvatore Sepe, Giorgio Ivan Russo, Peter R. Carroll, Ettore De Berardinis, Andrea Cocci, Fabio Galasso, Marina Di Mauro, Gabriele Iacona, Matteo Ferro, Maggi, Martina, Del Giudice, Francesco, Falagario, Ugo G, Cocci, Andrea, Russo, Giorgio Ivan, Di Mauro, Marina, Sepe, Giuseppe Salvatore, Galasso, Fabio, Leonardi, Rosario, Iacona, Gabriele, Carroll, Peter R, Cooperberg, Matthew R, Porreca, Angelo, Ferro, Matteo, Lucarelli, Giuseppe, Terracciano, Daniela, Cormio, Luigi, Carrieri, Giuseppe, De Berardinis, Ettore, Sciarra, Alessandro, and Busetto, Gian Maria

Subjects
Urologic Diseases, Aging, Cancer Research, medicine.medical_specialty, Prostate biopsy, Oncology and Carcinogenesis, 030232 urology & nephrology, Article, magnetic resonance, 03 medical and health sciences, Prostate cancer, PSA, 0302 clinical medicine, Clinical Research, Prostate, Biopsy, medicine, urinary biomarker, prostate biopsy, Overdiagnosis, early detection, RC254-282, Cancer, screening and diagnosis, medicine.diagnostic_test, business.industry, Prostate Cancer, biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Magnetic resonance imaging, medicine.disease, prostate cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, medicine.anatomical_structure, Oncology, prostate neoplasm, 030220 oncology & carcinogenesis, Biomarker (medicine), Prostate neoplasm, Radiology, mpMRI, business, 4.2 Evaluation of markers and technologies
Abstract

Simple Summary Prostate-specific antigen and digital rectal examination, used to guide prostate biopsy, often result in overdiagnosis of indolent prostate cancer (PCa) while missing clinically significant PCa (csPCa). The aim of this study was to evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance imaging (mpMRI) in predicting PCa in prostate biopsies. SelectMDx was revealed to be a good predictor of PCa, while with regards to csPCa detection, it was demonstrated to be less effective, showing results similar to mpMRI. The best diagnostic strategy to avoid unnecessary biopsy is performing SelectMDx after an initial negative mpMRI. Biopsy could be proposed for all cases of positive mpMRI and to those with a negative mpMRI followed by a positive SelectMDx. Abstract Prostate-specific antigen (PSA) testing as the sole indication for prostate biopsy lacks specificity, resulting in overdiagnosis of indolent prostate cancer (PCa) and missing clinically significant PCa (csPCa). SelectMDx is a biomarker-based risk score to assess urinary HOXC6 and DLX1 mRNA expression combined with traditional clinical risk factors. The aim of this prospective multi-institutional study was to evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance (mpMRI) when predicting PCa in prostate biopsies. Overall, 310 consecutive subjects were included. All patients underwent mpMRI and SelectMDx prior to prostate biopsy. SelectMDx and mpMRI showed sensitivity and specificity of 86.5% vs. 51.9%, and 73.8% vs. 88.3%, respectively, in predicting PCa at biopsy, and 87.1% vs. 61.3%, and 63.7% vs. 83.9%, respectively, in predicting csPCa at biopsy. SelectMDx was revealed to be a good predictor of PCa, while with regards to csPCa detection, it was demonstrated to be less effective, showing results similar to mpMRI. With analysis of strategies assessed to define the best diagnostic strategy to avoid unnecessary biopsy, SelectMDx appeared to be a reliable pathway after an initial negative mpMRI. Thus, biopsy could be proposed for all cases of mpMRI PI-RADS 4–5 score, and to those with Prostate Imaging-Reporting and Data System (PI-RADS) 1–3 score followed by a positive SelectMDx.

Published
2021

46. Systemic combining inflammatory score (SCIS): A new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer

Author

Francesco Soria, Michele Marchioni, Angelo Porreca, Sebastiano Cimino, Francesco Del Giudice, Matteo Muto, Giorgio Ivan Russo, Nicolae Crisan, Vincenzo Mirone, Abdal Rahman Abu Farhan, Matteo Ferro, Riccardo Autorino, Rodolfo Hurle, Gian Maria Busetto, Pierluigi Bove, Luigi Schips, Marco Borghesi, Francesco Cantiello, Sisto Perdonà, Giuseppe Lucarelli, Andrea Mari, Andrea Minervini, Giovanni Cordima, Ottavio De Cobelli, Alessandro Veccia, Marina Di Mauro, Rocco Damiano, Daniela Terracciano, Michele Battaglia, Gennaro Musi, Mihai Dorin Vartolomei, Giuseppe Morgia, Ferro, Matteo, Di Mauro, Marina, Cimino, Sebastiano, Morgia, Giuseppe, Lucarelli, Giuseppe, Abu Farhan, Abdal Rahman, Vartolomei, Mihai Dorin, Porreca, Angelo, Cantiello, Francesco, Damiano, Rocco, Busetto, Gian Maria, Del Giudice, Francesco, Hurle, Rodolfo, Perdonà, Sisto, Borghesi, Marco, Bove, Pierluigi, Autorino, Riccardo, Crisan, Nicolae, Marchioni, Michele, Schips, Luigi, Soria, Francesco, Mari, Andrea, Minervini, Andrea, Veccia, Alessandro, Battaglia, Michele, Terracciano, Daniela, Musi, Gennaro, Cordima, Giovanni, Muto, Matteo, Mirone, Vincenzo, de Cobelli, Ottavio, and Russo, Giorgio Ivan

Subjects
medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, Outcomes, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, In patient, Inflammation, Bladder cancer, Bladder cancer (BC), Immune system, Prognosis, business.industry, Hazard ratio, Cancer, Retrospective cohort study, medicine.disease, Settore MED/24, Reproductive Medicine, 030220 oncology & carcinogenesis, Concomitant, outcome, Original Article, Non muscle invasive, business, Adjuvant
Abstract

Background An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation. Methods A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3). Results After 48 months of follow-up (IQR 40.0-73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size >3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5%) received BCG, 266 (17.6%) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression. Conclusions The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality.

Published
2021

47. Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes

Author

Massimiliano Creta, Antonio Celia, Marina Di Mauro, Bernardino De Concilio, Tommaso Silvestri, Felice Crocetto, Maida Bada, Bada, Maida, De Concilio, Bernardino, Crocetto, Felice, Creta, Massimiliano, Silvestri, Tommaso, Di Mauro, Marina, and Celia, Antonio

Subjects
Carcinoma, Transitional Cell, medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, General surgery, Urinary Bladder, Urinary diversion, MEDLINE, Urinary Diversion, Cystectomy, Single Center, Extracorporeal, Treatment Outcome, Italy, Urinary Bladder Neoplasms, Nephrology, Humans, Medicine, Laparoscopy, business
Published
2020
Full Text
View/download PDF

48. Penile length and circumference dimensions: A large study in young Italian men.

Author

Di Mauro M, Tonioni C, Cocci A, Kluth LA, Russo GI, Gomez Rivas J, Cacciamani G, Cito G, Morelli G, Polloni G, di Maida F, and Giunti D

Subjects
Humans, Italy, Male, Regression Analysis, Penile Erection, Penis
Abstract

The aim of the present study was to evaluate the size of the penis in flaccidity and in erection of Italian men. A total of 4,685 men living in Italy and who have been visited at the Italian urology operating units were involved in the study between January 2019 and January 2020. Each patient was given details on how to measure their penis (erect length and circumference) in flaccidity and in erection, from the lower base to the distal penile tip. Mean (standard deviation [SD]) flaccid penis length was 9.47 (2.69), mean (SD) flaccid penis circumference was 9.59 (3.08), mean (SD) erect penis length was 16.78 (2.55) and mean (SD) erect penis circumference was 12.03 (3.82). At the linear regression analysis, height was associated with flaccid penis length (β = 0.04; p-value = .01), and erect penis length was (β = 0.05; p-value < .01) and erect penis circumference was (β = 0.06; p-value < .01). Height is proportional to the length of the penis in flaccidity and in erection, and to the circumference in erection. The increase in BMI leads to a reduction in the length of the erect penis, as well as weight gain reduces the length of the flaccid penis., (© 2021 The Authors. Andrologia published by Wiley-VCH GmbH.)

Published
2021
Full Text
View/download PDF

49. Impact of the COVID-19 pandemic on the sexual behavior of the population. The vision of the east and the west.

Author

Ibarra FP, Mehrad M, Di Mauro M, Godoy MFP, Cruz EG, Nilforoushzadeh MA, and Russo GI

Subjects
Betacoronavirus, COVID-19, Humans, Iran, Italy, Pandemics, SARS-CoV-2, Spain, Coronavirus Infections epidemiology, Pneumonia, Viral epidemiology, Sexual Behavior
Abstract

The COVID-19 pandemic has radically changed the way of life around the World. The state of alarm has forced the population to stay at home, radically changing both interpersonal and partner relationships; work at home, social distancing, the continued presence of children at home, fear of infection and not being able to physically meet with others have changed most people's sexual habits. We conducted a review by exploring the impact of the COVID-19 pandemic on sexual behavior in the population from three different countries: Iran, Italy and Spain from each country's perspective. The impact of the coronavirus will be very important in the sexual life of the people and we will attend in the next months or years, to some changes in the relationships at all the levels. The pandemic will negatively affect sexual behaviors due to multiple contact restrictions. In the future, we will be able to assess these effects in more detail., Competing Interests: None declared., (Copyright® by the International Brazilian Journal of Urology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results